CANbridge Pharmaceuticals Inc. (1228.HK)
| Previous close | 0.455 |
| Open | 0.455 |
| Bid | 0.445 x N/A |
| Ask | 0.450 x N/A |
| Day's range | 0.445 - 0.455 |
| 52-week range | 0.250 - 2.030 |
| Volume | |
| Avg. volume | 43,983 |
| Market cap | 191.053M |
| Beta (5Y monthly) | -0.53 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.960 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 7.16 |
PR NewswireCANbridge Announces NDA Acceptance of CAN108 (邁芮倍®/LIVMARLI®) for Cholestatic Pruritus in Progressive Familial Intrahepatic Cholestasis (PFIC) by China's National Medical Products Administration
CANbridge Pharmaceuticals Inc. (HKEX:1228), a global biopharmaceutical company, with a foundation in China, committed to the research, development and commercialization of transformative rare disease and rare oncology therapies, announced today that the National Medical Products Administration of China (NMPA) has accepted the New Drug Application (NDA) for CAN108 (Maralixibat Chloride Oral Solution /迈芮倍®/LIVMARLI®) for the treatment of cholestatic pruritus in patients two months of age and older
PR NewswireCANbridge Announces Full Enrollment Reached in the Core Part of The CAN103 Phase 2 Trial for Gaucher Disease in China
CANbridge Pharmaceuticals Inc. (1228.HK), a global biopharmaceutical company, with a foundation in China, committed to the research, development and commercialization of transformative therapies to treat rare disease and rare oncology, announced that the core part of the ongoing CAN103 Phase 2 trial, in treatment-naïve patients aged 12 or above with Gaucher disease (GD) Types I and III, has reached full enrollment. Phase 2 is a randomized, double-blind, dose comparison study to evaluate the effi
- PR Newswire
CANbridge Announces Marketing Approval of CAN108 (/LIVMARLI®) in Taiwan for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome (ALGS)
CANbridge Pharmaceuticals Inc. (1228.HK), a global biopharmaceutical company, with a foundation in China, committed to the research, development and commercialization of transformative therapies to treat rare diseases and oncology, today announced the marketing approval of CAN108 (Maralixibat Chloride Oral Solution /LIVMARLI®) by the Taiwan Food and Drug Administration (TFDA). LIVMARLI is a minimally absorbed ileal bile acid transporter (IBAT) inhibitor, and the first and only treatment approved
